Triple
T14422190
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | FamilyTreeDNA |
E357610
|
entity |
| Predicate | brandOf |
P1500
|
FINISHED |
| Object | Gene by Gene, Ltd. |
E1099453
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Gene by Gene, Ltd. | Statement: [FamilyTreeDNA, brandOf, Gene by Gene, Ltd.]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Gene by Gene, Ltd. Context triple: [FamilyTreeDNA, brandOf, Gene by Gene, Ltd.]
-
A.
Gene by Gene, Ltd.
chosen
Gene by Gene, Ltd. is a genetic testing company known for providing DNA analysis services for ancestry, health, and research applications.
-
B.
Genex
Genex is an airline that uses Minsk National Airport as a primary base of operations for its flight network.
-
C.
Genivar Inc.
Genivar Inc. was a Canadian engineering and professional services firm that grew through acquisitions and later rebranded as WSP Global.
-
D.
NewLink Genetics
NewLink Genetics is a biopharmaceutical company known for developing immuno-oncology therapies and infectious disease vaccines, including holding rights to the rVSV-ZEBOV Ebola vaccine candidate.
-
E.
Genocea Biosciences
Genocea Biosciences is a biotechnology company that develops T cell–targeted vaccines and immunotherapies using a proprietary antigen discovery platform.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d82793421c8190861eb0e673b085de |
completed | April 9, 2026, 10:26 p.m. |
| NER | Named-entity recognition | batch_69de91102c3c81908f571a1fff3bdd47 |
completed | April 14, 2026, 7:10 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69fd648784048190a9c7e95bfeec8b23 |
completed | May 8, 2026, 4:20 a.m. |
Created at: April 10, 2026, 1:18 a.m.